Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HOB Biotech GroupSHSE:688656 +2.94%83 EV-to-EBITDA is 198.09 as of Aug. 31, 2026, which is 322% above its 10-year median of 46.89. GuruFocus rates SHSE:688656 with a GF Score™ of 83/100 and a GF Value™ of ¥94.67 (Fairly Valued). The stock has 5 warning signs investors should review. Among 520 Medical Devices & Instruments companies, HOB Biotech Group ranks worse than 97.69% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, HOB Biotech Group's enterprise value is ¥6,092.9 Mil.
HOB Biotech Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥30.8 Mil. Therefore, HOB Biotech Group's EV-to-EBITDA for today is 198.09.
The historical rank and industry rank for HOB Biotech Group's EV-to-EBITDA or its related term are showing as below:
SHSE:688656'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.93 Med: 46.89 Max: 382.06
Current: 198.09
During the past 10 years, the highest EV-to-EBITDA of HOB Biotech Group was 382.06. The lowest was 16.93. And the median was 46.89.
SHSE:688656's EV-to-EBITDA is ranked worse than 97.69% of 520
companies
in the Medical Devices & Instruments industry
Industry Median: 14.68
vs SHSE:688656: 198.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
HOB Biotech Group (SHSE:688656) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HOB Biotech Group's PE Ratio (TTM) for today is calculated as:
HOB Biotech Group's share price for today is ¥96.44.
HOB Biotech Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for HOB Biotech Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688656 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, HOB Biotech Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOB Biotech Group EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HOB Biotech Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HOB Biotech Group's EV-to-EBITDA falls into.
HOB Biotech Group's current Enterprise Value is ¥6,092.9 Mil.
HOB Biotech Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥30.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOB Biotech Group (SHSE:688656) has a EV-to-EBITDA of 198.09 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on HOB Biotech Group. This is 322% above median its historical median of 46.89. Over the past decade, HOB Biotech Group's EV-to-EBITDA has ranged from 16.93 to 382.06. According to the industry distribution chart, HOB Biotech Group ranks #508 out of 520 companies in the Medical Devices & Instruments industry, placing it in the top 97.7%.
Is HOB Biotech Group's EV-to-EBITDA too high?
HOB Biotech Group's current EV-to-EBITDA of 198.09 is 322% above median its 10-year median of 46.89. Over the past 10 years, this metric has ranged from a low of 16.93 to a high of 382.06. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.68. HOB Biotech Group's value of 198.09 is 1249.4% above this industry median. Based on the distribution chart, HOB Biotech Group ranks #508 out of 520 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, HOB Biotech Group has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HOB Biotech Group's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HOB Biotech Group ranks #508 out of 520 companies for EV-to-EBITDA. This places HOB Biotech Group in the lower half of its industry. The industry median EV-to-EBITDA is 14.68. HOB Biotech Group's value of 198.09 is 1249.4% above this benchmark. Historically, HOB Biotech Group's own EV-to-EBITDA has ranged from 16.93 to 382.06 over the past decade. While the company's 10-year median is 46.89 vs. the industry median of 14.68, HOB Biotech Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.68, based on 520 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOB Biotech Group's current EV-to-EBITDA of 198.09 is 1249.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on HOB Biotech Group. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOB Biotech Group's current EV-to-EBITDA is 198.09, which is 322% above median its own 10-year median of 46.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOB Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, HOB Biotech Group (SHSE:688656) is currently considered Fairly Valued. The stock's GF Value™ is ¥94.67, compared to a current price of ¥96.44 — trading 1.9% above its estimated fair value. The current EV-to-EBITDA is 198.09, which is 322% above median its 10-year median of 46.89 and 1249.4% above the Medical Devices & Instruments industry median of 14.68. HOB Biotech Group's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For HOB Biotech Group (SHSE:688656), the current EV-to-EBITDA is 198.09 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOB Biotech Group (SHSE:688656) Overvalued in 2026?
Based on GuruFocus' analysis, HOB Biotech Group stock appears to be overvalued.
The current stock price of ¥96.44 is trading 1.9% above its estimated GF Value™ of ¥94.67.
GuruFocus considers HOB Biotech Group to be Fairly Valued.
Key valuation signals for SHSE:688656:
EV-to-EBITDA: 198.09 (322% above median its 10-year median of 46.89)
GF Value™: ¥94.67 vs. price of ¥96.44 (1.9% above fair value)
Industry Position: 1249.4% above the Medical Devices & Instruments median (#508 of 520)
No single metric tells the full story. See the SHSE:688656 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOB Biotech Group Corp Ltd is an in vitro diagnostic company. The firm is specialized in providing diagnostic tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care.
83GF Score
Get the complete analysis for SHSE:688656
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688656 has been successfully added to your 
